Trial Profile

Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pfs25 malaria vaccine MVI (Primary) ; Aluminium hydroxide; Hepatitis B vaccine recombinant; Meningococcal vaccine groups A C Y W-135 conjugate
Indications Falciparum malaria
Focus Adverse reactions

23 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
08 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.
08 Jul 2015 Planned primary completion date changed from 1 Jun 2015 to 1 Jun 2016 as per ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com